AbbVie / Genmab – European Approval of TEPKINLY + R2 in R/R Follicular Lymphoma
The European Commission approved TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab (R2) for adults with relapsed or refractory follicular lymphoma. The approval is supported by the Phase 3 EPCORE FL-1 trial, where TEPKINLY…
